The deal gives Mylan a wide array of
Abbott brands in developed markets outside the
United States that have annual sales of almost $2 billion, including pain drug Brufen and
influenza vaccine In...
Regardless of whether the deal arises from friendly negotiations or a
hostile approach, it is likely to end on good terms if successfully
completed, Pfizer Chief Executive Ian Read said.
The two drugmakers have resumed talks about a trans-Atlantic merger after Pfizer sweetened the terms of an earlier takeover offer for its British rival.